CTLA4 and melanoma: Apart from the combination with anti-PD-1, a clinical retrospective study of 101 advanced melanoma patients treated with ipilimumab (anti-CTLA-4) showed that the response rate and OS were significantly higher in the 70 patients who received RT during treatment [154].